Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment —Analyses from the German clinical RCC-Registry
Although renal cell carcinoma (RCC) represents only approximately 4% of adult malignancies in Europe, it displays the highest mortality rate of all urologic tumors with 40% of RCC patients dying from the disease [1]. In Germany, about 15,100 people are expected to be diagnosed with RCC in 2018 and an estimated 5,400 patients will die of kidney cancer each year [2]. As RCC does not immediately lead to clinical symptoms, about 20% to 30% of RCC patients present with advanced or metastatic disease (mRCC) at diagnosis [3] and about 20% of patients diagnosed with localized disease will subsequently develop metastases [4,5].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Peter J. Goebell, Lothar M üller, Andreas Hübner, Hanns-Detlev Harich, Emil Boller, Michaela Koska, Martina Jänicke, Norbert Marschner, the RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma) Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Germany Health | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology